

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PFE | NYSE | USD | Real-time | |
PFE | Mexico | MXN | Delayed | |
PFE | Stockholm | SEK | Real-time | |
PFE | Frankfurt | EUR | Delayed | |
PFE | TradeGate | EUR | Delayed | |
PFE | Hamburg | EUR | Delayed | |
PFE | Xetra | EUR | Delayed | |
PFE | Santiago | USD | Delayed | |
PFE | Buenos Aires | ARS | Delayed | |
PFIZ34 | BM&FBovespa | BRL | Delayed | |
PFE | Vienna | EUR | Delayed | |
PFE_KZ | KASE | USD | Delayed | |
PFE | Colombia | COP | Delayed | |
PFE | Lima | USD | Delayed |
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
Name | Age | Since | Title |
---|---|---|---|
Susan J. Hockfield | 70 | 2020 | Independent Director |
Daniel R. Littman | 69 | 2018 | Independent Director |
Albert Bourla | 60 | 2016 | Chairman of the Board & CEO |
Suzanne M. Nora Johnson | 65 | 2007 | Independent Director |
Ronald E. Blaylock | 62 | 2017 | Independent Director |
James C. Smith | 62 | 2014 | Independent Director |
Shantanu Narayen | 58 | 2013 | Lead Independent Director |
Helen H. Hobbs | 70 | 2011 | Independent Director |
Joseph J. Echevarria | 65 | 2015 | Independent Director |
James Robert B. Quincey | 57 | 2020 | Independent Director |
Scott Gottlieb | 49 | 2019 | Independent Director |
Charles T. Hagel | 76 | - | Member of Emerging Markets Advisory Board |
Susan Desmond-Hellmann | 65 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review